Covid 19 Research using Clinical Trials (Home Page)
HB-adMSCsWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug193 | Chloroquine analog (GNS651) Wiki | 0.71 |
| drug555 | Nivolumab Wiki | 0.50 |
| drug775 | Standard of care Wiki | 0.25 |
| drug632 | Placebos Wiki | 0.19 |
| drug854 | Tocilizumab Wiki | 0.18 |
| drug360 | Hydroxychloroquine Wiki | 0.09 |
| drug616 | Placebo Wiki | 0.07 |
Correlated MeSH Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009362 | Neoplasm Metastasis NIH | 0.71 |
| D012141 | Respiratory Tract Infections NIH | 0.18 |
| D003141 | Communicable Diseases NIH | 0.17 |
| D007239 | Infection NIH | 0.12 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
NCT04348435 COVID-19 Drug: HB-adMSCs Drug: Placebos
Primary Outcomes
Description: Number of subjects that must be hospitalized for COVID-19 during the conduct of this study
Measure: Incidence of hospitalization for COVID-19 Time: week 0 through week 26 (end of study)Description: Number of subjects who experience symptoms defined to be associated with COVID-19, such as fever, shortness of breath/difficulty breathing, cough.
Measure: Incidence of symptoms associated with COVID-19 Time: week 0 through week 26 (end of study)Secondary Outcomes
Description: Number of subjects that develop upper/lower respiratory infection with hospitalization criteria
Measure: Absence of upper/lower respiratory infection Time: week 0 through week 26Description: change from baseline in leukocyte differential
Measure: Leukocyte differential Time: weeks 0, 6, 14, 26Description: change from baseline in C Reactive protein
Measure: C Reactive protein Time: weeks 0, 6, 14, 26Description: change from baseline in TNF alpha
Measure: TNF alpha Time: weeks 0, 6, 14, 26Description: change from baseline in IL-6
Measure: IL-6 Time: weeks 0, 6, 14, 26Description: change from baseline in IL-10
Measure: IL-10 Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of glucose in the blood (mg/dL)
Measure: Glucose Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of calcium in the blood (mg/dL)
Measure: Calcium Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of albumin in the blood (g/dL)
Measure: Albumin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total protein in the blood (g/dL)
Measure: Total protein Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of sodium in the blood (mol/L)
Measure: Sodium Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total carbon dioxide in the blood (mmol/L)
Measure: Total carbon dioxide Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of potassium in the blood (mmol/L)
Measure: Potassium Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of chloride in the blood (mmol/L)
Measure: Chloride Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of BUN in the blood (mg/dL)
Measure: BUN Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of creatinine in the blood (mg/dL)
Measure: Creatinine Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)
Measure: Alkaline phosphatase Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)
Measure: Alanine aminotransferase Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total bilirubin in the blood (mg/dL)
Measure: Total bilirubin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)
Measure: white blood cells Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)
Measure: red blood cells Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hemoglobin in the blood (g/dL)
Measure: hemoglobin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hematocrit in the blood (%)
Measure: hematocrit Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular volume in the blood (fL)
Measure: mean corpuscular volume Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)
Measure: mean corpuscular hemoglobin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin concentration in the blood (g/dL)
Measure: mean corpuscular hemoglobin concentration Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of red cell distribution width in the blood (%)
Measure: red cell distribution width Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of neutrophils in the blood (%)
Measure: neutrophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of lymphocytes in the blood (%)
Measure: Lymphs Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of monocytes in the blood (%)
Measure: Monocytes Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of eosinophils in the blood (%)
Measure: Eosinophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of basophils in the blood (%)
Measure: Basophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)
Measure: Absolute neutrophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute lymphocytes in the blood (x 10^3/uL)
Measure: Absolute lymphs Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)
Measure: Absolute monocytes Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)
Measure: Absolute eosinophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)
Measure: Absolute basophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of immature granulocytes in the blood (x 10^3/uL)
Measure: Immature granulocytes Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of platelets in the blood (x 10^3/uL)
Measure: Platelets Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of time for blood to coagulate (seconds)
Measure: Prothrombin time Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of international normalized ratio of blood coagulation (no unit)
Measure: INR Time: weeks 0, 6, 14, 26Description: Short-form 36 Health Survey; scored on a scale of 0-100; lower score equals more disability
Measure: SF-36 Time: weeks 0, 6, 14, 26Description: Depression module; scores DSM-IV criteria 0-3 to monitor severity of depression
Measure: PHQ-9 Time: weeks 0, 6, 14, 262 A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
NCT04349631 COVID-19 Drug: HB-adMSCs
Primary Outcomes
Description: Number of subjects that require hospitalization for COVID-19
Measure: Incidence of hospitalization for COVID-19 Time: Week 0 through week 26 (end of study)Description: Number of subjects that develop symptoms associated with COVID-19, such as fever, shortness of breath/difficulty breathing, cough
Measure: Incidence of symptoms for COVID-19 Time: week 0 through week 26 (end of study)Secondary Outcomes
Description: absence of upper/lower respiratory infection by hospitalization criteria
Measure: absence of upper/lower respiratory infection Time: Weeks 0 through 26Description: clinical lab evaluation of level of glucose in the blood (mg/dL)
Measure: Glucose Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of calcium in the blood (mg/dL)
Measure: Calcium Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of albumin in the blood (g/dL)
Measure: Albumin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total protein in the blood (g/dL)
Measure: Total Protein Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of sodium in the blood (mol/L)
Measure: Sodium Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of carbon dioxide in the blood (mmol/L)
Measure: Total carbon dioxide Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of potassium in the blood (mmol/L)
Measure: Potassium Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of chloride in the blood (mmol/L)
Measure: Chloride Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of BUN in the blood (mg/dL)
Measure: BUN Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of creatinine in the blood (mg/dL)
Measure: Creatinine Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)
Measure: Alkaline phosphatase Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)
Measure: Alanine aminotransferase Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of aspartate aminotransferase in the blood (IU/L)
Measure: Aspartate aminotransferase Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total bilirubin in the blood (mg/dL)
Measure: Total bilirubin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)
Measure: White blood cells Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)
Measure: Red blood cells Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hemoglobin in the blood (g/dL)
Measure: Hemoglobin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hematocrit in the blood (%)
Measure: Hematocrit Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular volume in the blood (fL)
Measure: Mean corpuscular volume Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)
Measure: Mean corpuscular hemoglobin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin in the blood (g/dL)
Measure: Mean corpuscular hemoglobin concentration Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of red blood cell distribution width in the blood (%)
Measure: Red cell distribution width Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of neutrophils in the blood (%)
Measure: Neutrophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of lymphocytes in the blood (%)
Measure: Lymphs Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of monocytes in the blood (%)
Measure: Monocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of eosinophils in the blood (%)
Measure: Eos Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of basophils in the blood (%)
Measure: Basophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)
Measure: Absolute neutrophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute lymphs in the blood (x 10^3/uL)
Measure: Absolute lymphs Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)
Measure: Absolute monocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)
Measure: Absolute eosinophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)
Measure: Absolute basophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of granulocytes in the blood (%)
Measure: Immature granulocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of granulocytes in the blood (x 10^3/uL)
Measure: Absolute Immature granulocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of platelets in the blood (x 10^3/uL)
Measure: Platelets Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of time for blood to coagulate (seconds)
Measure: Prothrombin time Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of international normalized ratio of blood coagulation (no unit)
Measure: INR Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of tumor necrosis factor alpha in the blood (pg/mL)
Measure: TNFalpha Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of interleukin-6 in the blood (pg/mL)
Measure: Interleukin-6 Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of interleukin-10 in the blood (pg/mL)
Measure: Interleukin-10 Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of interleukin-10 in the blood (mg/L)
Measure: C-reactive protein Time: Weeks 0, 6, 14, 26Description: Short-form 36 Health Survey; scored on a scale of 0-100; lower score equals more disability.
Measure: SF-36 Time: Weeks 0, 6, 14, 26Description: Depression module; scores DSM-IV criteria 0-3 to monitor severity of depression.
Measure: PHQ-9 Time: Weeks 0, 6, 14, 26